Maria Grazia Pascucci
Research Interests
Maria Grazia Pascucci has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Caterina Rizzo
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
2 shared publications - Gabriella Frasca
Public Health Unit Emilia-Romagna Region, Viale Aldo Moro 21, 40127 Bologna, Italy
2 shared publications - Lorenza Ferrara
Regional Epidemiology Reference Service for the Surveillance, Prevention and Control of Infectious Diseases—Local Health Unit of Alessandria, 15121 Alessandria, Italy
2 shared publications - Tolinda Gallo
Department of Prevention, Local Health Unit 4 Medio Friuli, Udine, Italy
2 shared publications - Alba Carola Finarelli
Regional Health Authority; Bologna, Italy
1 shared publication - Angela Chiereghin
Governance of Screening Programs Unit, Health Management Staff, Local Health Authority of Bologna, Via Montebello 6, Bologna, 40121, Italy
1 shared publication
Latest Publications
- Open Access
- 22 December 2018
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 1-9
Active surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season
Surveillance for adverse events following immunization is an important component of any national immunization programme because it is critical to assessing the safety of vaccines and to detecting potentially rare and severe adverse events and responding in a timely manner. We conducted an enhanced active surveillance aimed at assessing the safety of flu vaccines in the 2015–2016 season in Italy. The study was targeted to the population groups for which the seasonal vaccine is recommended in Italy. During the study period, a total of 3213 individuals receiving seasonal influenza vaccination were registered on the web-based platform. Any adverse events experienced after 7 days from vaccination by individuals aged six months or more were collected through a telephone interview or by a web-based self-administered questionnaire. All individuals experiencing at least one event during the 7 days of follow-up were contacted for follow-up to 60 days. Overall, 854 events were reported: 845 events (26%) after administration of the first dose and 9 (12%) after the second dose. The majority of adverse events reported after 7 days from the first dose were of little clinical importance, and most involved local symptoms. Our data, even though the number of vaccinated individuals was smaller than expected, is consistent with the safety of influenza vaccines in Italy during the 2015–2016 season regarding the most common adverse events. Further efforts are needed to obtain sufficient power to study rarer adverse events. Active monitoring and systematic studies to test generated signals and hypotheses are crucial to intensify awareness among the public and professionals with regard to the safety of vaccines.
- 22 December 2018
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 1-9
Open AccessActive surveillance for safety monitoring of seasonal influenza vaccines in Italy, 2015/2016 season
Surveillance for adverse events following immunization is an important component of any national immunization programme because it is critical to assessing the safety of vaccines and to detecting potentially rare and severe adverse events and responding in a timely manner. We conducted an enhanced active surveillance aimed at assessing the safety of flu vaccines in the 2015–2016 season in Italy. The study was targeted to the population groups for which the seasonal vaccine is recommended in Italy. During the study period, a total of 3213 individuals receiving seasonal influenza vaccination were registered on the web-based platform. Any adverse events experienced after 7 days from vaccination by individuals aged six months or more were collected through a telephone interview or by a web-based self-administered questionnaire. All individuals experiencing at least one event during the 7 days of follow-up were contacted for follow-up to 60 days. Overall, 854 events were reported: 845 events (26%) after administration of the first dose and 9 (12%) after the second dose. The majority of adverse events reported after 7 days from the first dose were of little clinical importance, and most involved local symptoms. Our data, even though the number of vaccinated individuals was smaller than expected, is consistent with the safety of influenza vaccines in Italy during the 2015–2016 season regarding the most common adverse events. Further efforts are needed to obtain sufficient power to study rarer adverse events. Active monitoring and systematic studies to test generated signals and hypotheses are crucial to intensify awareness among the public and professionals with regard to the safety of vaccines.
- 1 August 2016
- Published by Elsevier in Journal of Clinical Virology
- Vol. 81, 34-42
Molecular detection and genetic characterization of circulating measles virus in northern Italy
- 1 August 2016
- Published by Elsevier in Journal of Clinical Virology
- Vol. 81, 34-42
Molecular detection and genetic characterization of circulating measles virus in northern Italy
- Open Access
- 30 December 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (3) , 671-676
Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy
The incidence of reported meningococcal disease in Italy is among the lowest in Europe. The trend of the disease was increasing up to 2005 and then declined after the gradual introduction of a universal Men C vaccination program in 17/21 Italian regions. Since 2006, in Emilia-Romagna region vaccination against Neisseria meningitidis serogroup C was actively offered free of charge in a single dose to the age groups 12–15 months and 14–15 years, in addition to people with defined epidemiological risk. Our aim was to measure the impact of vaccination on the incidence of meningococcal disease caused by different serogroups among the population of Emilia Romagna Region, Northern Italy (approximately 4.5 million inhabitants) subdivided by age. Using surveillance data, we computed the incidence rates of Neisseria meninigitidis related invasive disease per 100.000 inhabitants for the years 2000 to 2012. In addition, the percentage change in incidence and the mortality rates were calculated. Results indicate a 70.1% decrease in the incidence of meningococcus C-related invasive disease after the introduction of MenC universal vaccination. No case of serogroup C related infection was observed since 2006 in children aged 1–4 years. These findings suggest that the single-dose vaccination strategy against serogroup C N.meningitidis targeted to the age groups 12–15 months and 14–15 years was effective in the Emilia-Romagna population. However, the occurrence of two cases of meningiditis in a 5-month child and in a 9-years child suggests caution and careful consideration in surveillance for the next years.
- 30 December 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (3) , 671-676
Open AccessImpact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy
The incidence of reported meningococcal disease in Italy is among the lowest in Europe. The trend of the disease was increasing up to 2005 and then declined after the gradual introduction of a universal Men C vaccination program in 17/21 Italian regions. Since 2006, in Emilia-Romagna region vaccination against Neisseria meningitidis serogroup C was actively offered free of charge in a single dose to the age groups 12–15 months and 14–15 years, in addition to people with defined epidemiological risk. Our aim was to measure the impact of vaccination on the incidence of meningococcal disease caused by different serogroups among the population of Emilia Romagna Region, Northern Italy (approximately 4.5 million inhabitants) subdivided by age. Using surveillance data, we computed the incidence rates of Neisseria meninigitidis related invasive disease per 100.000 inhabitants for the years 2000 to 2012. In addition, the percentage change in incidence and the mortality rates were calculated. Results indicate a 70.1% decrease in the incidence of meningococcus C-related invasive disease after the introduction of MenC universal vaccination. No case of serogroup C related infection was observed since 2006 in children aged 1–4 years. These findings suggest that the single-dose vaccination strategy against serogroup C N.meningitidis targeted to the age groups 12–15 months and 14–15 years was effective in the Emilia-Romagna population. However, the occurrence of two cases of meningiditis in a 5-month child and in a 9-years child suggests caution and careful consideration in surveillance for the next years.